Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial
18 de jul. de 2023 ·
9m 7s
Regístrate gratis
Escucha este episodio y muchos más. ¡Disfruta de los mejores podcasts en Spreaker!
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was...
mostra más
Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was an open-label, multicenter, randomized study evaluated the quality of life prospectively in Crohn’s patients who treated with Ustekinumab.
mostra menos
Información
| Autor | UEG Journal |
| Página web | - |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
